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Abstract: Annovera (segesterone acetate and ethinyl estradiol vaginal system) is a US Food and Drug
Administration FDA-approved long-lasting, reversible contraceptive that is fully administered by the
user and does not require a procedure for insertion or removal. The vaginal system is in the shape of
a ring and contains low doses of a novel progestin, egesterone acetate, and ethinyl estradiol. It is
made of silicone and is fully pliable and flexible. The vaginal system is reusable for 13 cycles, using a
21 days in/7 days out regimen, providing women with the ability to control their fertility. Particularly
now during the COVID-19 pandemic when access to contraception has been further reduced, patients
may benefit from a method that is both long-lasting and patient-controlled.
Keywords: Annovera; contraception; Combined Hormonal Contraception (CHC); vaginal ring;
family planning; birth control; hormonal contraception; vaginal system

1. Introduction
Approximately 45% of pregnancies in the United States are unintended [1]. This high rate of
unintended pregnancies underscores the need to develop contraceptive methods that meet the needs of
women. While over 99% of sexually active women (ages 14 to 44) have used at least one contraceptive
method in their lifetime, only 60% of women are actively using contraception [2]. Additionally,
many women do not use contraceptive products consistently, with 41% of unintended pregnancies
caused by inconsistent use of contraceptives [3]. This can partly be attributed to resupply challenges.
In a 2011 study, 38.5% of women using the pill, patch, or ring had two or more late refills during
an 18 month period [4]. Short-acting contraceptive methods are typically dispensed in only 1- or
3-month supplies; therefore, women are required to make multiple trips to their clinic or pharmacy for
continued access. These additional trips introduce a potential barrier to consistent use, as woman who
are late to start their next month’s regimen of contraception will be at an increased risk of pregnancy.
To address this issue, the Centers for Disease Control recommend that women be provided with a
1-year supply of birth control [5]. Studies have shown that women who receive a 1-year supply are
30% less likely to have an unintended pregnancy compared to women who receive a 1 to 3 month
supply [6,7].
Another strategy to reduce unintended pregnancies is to increase the use of long-acting reversible
contraception (LARC) methods such as intrauterine devices (IUDs) and implants. While these methods
are highly effective, they must be administered by a healthcare professional and require a procedure for
insertion and removal. This can create access issues for some patients since only 56% of office-based
Pharmacy 2020, 8, 156; doi:10.3390/pharmacy8030156
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OB/GYNs, family practitioners, and adolescent medicine specialists offer on-site IUDs, and only 32%
offer implants [8]. Given the limitations associated with these methods, women may benefit from a
contraceptive option that is long-lasting, patient-controlled, and procedure-free.
Yet another strategy to improve patient access to contraception and subsequently reduce
unintended pregnancies has been to implement legislation to expand the scope of pharmacists, allowing
them to directly prescribe and dispense hormonal contraception without a medical prescription [9].
This strategy removes several access barriers for patients and is a service that is safe and desired by
patients. Receiving healthcare directly from a pharmacist does not require an appointment, and many
pharmacies have hours that are expanded from typical medical clinic hours, allowing patients to
seek services at times that are convenient for them. Additionally, findings from a recent study show
that women receiving contraception from pharmacists were younger, had less education, and were
more likely to be uninsured than women seeing traditional healthcare providers [10]. It has also been
found that patients who receive a 6 month or greater supply of contraception have higher rates of
contraceptive continuation and adherence [6,10]. These findings suggest that the pharmacist prescribing
of contraception allows for an improved access to birth control methods, especially in underserved
populations, and provides a promising strategy to promote consistent use of contraception [11].
Furthermore, patients are receptive to the idea of pharmacists prescribing their birth control method.
The results of a national survey of women at risk for unintended pregnancy found that 68% of women
liked the idea of being able to obtain contraception directly from a pharmacist, without having to visit a
healthcare provider first [12]. Lastly, this is a safe practice. The safety of hormonal contraception is well
established, and research has shown that pharmacists are able to safely assess medical contraindications
for hormonal contraceptive use and patients are also able to safely self-screen for contraindications to
hormonal contraceptive use [13,14].
In addition to typical barriers patients may encounter when attempting to seek contraception,
the COVID-19 pandemic has led to sweeping changes across the country, including reduced access to
healthcare and the loss of employment and health insurance for millions of Americans. Women have
been disproportionately affected by the current health crisis and have been more likely than men to
have lost their jobs [15]. According to a recent national survey conducted by the Guttmacher Institute,
pandemic-related stress related to finances, job stability, and insecurity about the future has also led to
a shift in how women feel about having children. More than 40% of women reported that because of
the COVID-19 pandemic, they have changed their plans about when to have children or how many
children to have, with 34% wanting to get pregnant later or wanting fewer children because of the
pandemic. Thirty-three percent of women reported that they had trouble getting their birth control or
had to delay or cancel visiting their healthcare provider for reproductive healthcare. Overall, 23% of
women reported thinking more about getting a longer-acting contraceptive method [16]. In light of
these findings, a long-lasting, patient-controlled, procedure-free method of contraception is especially
relevant in the current climate.
Annovera is a new contraception method that was FDA-approved in 2018 and is available currently
in the United States. Annovera is a soft, flexible ring that is self-administered and does not require a
procedure. It is inserted into the vagina and remains in place for 21 days and then removed for 7 days.
Upon removal, the ring is washed and stored in its case at room temperature; due to the method in
which the steroids are dispersed in the ring, it does not require refrigeration at any time [17]. The same
ring can be reused for up to a full year or 13 menstrual cycles [17]. As such, the patient can obtain a
year’s supply of contraception at the pharmacy that is reversible and fully under the patient’s control.
This article will review the clinical data supporting Annovera and provide best practices for patient
counseling tailored to pharmacists.
2. Composition of Annovera
Annovera is composed of a silicone elastomer vaginal ring that is opaque white in color (Figure 1).
It measures 56 mm in outside diameter and 8.4 mm in cross-sectional diameter. The ring body contains
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The Pearl Index for the primary efficacy group was 2.98 (CI: 2.13, 4.06) per 100 woman-years
[22]; Annovera’s contraceptive efficacy was comparable to other combined hormonal contraceptives
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and decreased as age increased. Patients older than 35 years had a Pearl Index of 0.99 (95% CI 0.06–4.34).
The Pearl Index was not influenced by BMI [22].
Kaplan–Meier analysis determined that Annovera is 97.5% effective [22]. Furthermore, pregnancy
occurrence was similar across all cycles [22].
4.2. Patient Acceptability
An acceptability substudy was also performed to determine whether this method of contraception
could be considered a successful option in meeting the reproductive needs of patients, as well as
identify factors associated with successful use of Annovera. Overall, 89% of patients were satisfied
with their use of Annovera [23]. Satisfaction was related to ease of use, side effects, expulsions/feeling
the product, and physical effect during sexual activity [23]. After the study, 78% of women indicated
that they would prefer to use Annovera as their choice of contraception moving forward [23].
In terms of the effect of Annovera on sexual activity, 69% of women in the clinical trials reported
that they never felt Annovera during intercourse [24]. Additionally, 84% of women reported no change
or an increase in sexual activity, and 86% of women reported no change or an increase in sexual
pleasure with Annovera [24]. Most women, 78%, reported that Annovera never affected their partner’s
sexual pleasure [24]. Given this data, patients can be counseled to leave Annovera in place during
sexual activity.
This acceptability substudy also helped to identify several key topics that are important to include
in the patient counseling conversation. While most women reported that Annovera was easy to use,
problems with ring removal were associated with dissatisfaction, indicating that it is equally important
to counsel patients about the appropriate technique for both insertion and removal [23]. This discussion
is also important whether the patient has had previous experiences with vaginal rings and/or tampons;
there was no association between prior use of vaginal rings or tampons and satisfaction and adherence
to Annovera [23].
Anticipatory guidance about the possibility of Annovera expelling and/or feeling Annovera is
also important. Patients who felt Annovera while it was in place in the vagina were more likely to be
dissatisfied [23]. As such, it is important to counsel patients that Annovera should be positioned in
the upper two-thirds of the vagina and that they should not feel it after insertion. Counseling about
the possibility of expulsions, especially during voiding, undertaking activities that require straining,
or performing certain daily activities, such as squatting, should also be included in the counseling
conversation [23].
4.3. Bleeding Profile
Bleeding patterns associated with Annovera were well tolerated. When the vaginal system
was removed cyclically as directed, 98% of women had predictable, scheduled bleeding [25].
Women experienced an average of 3.3 bleeding days per cycle [25]. Unscheduled bleeding and
spotting occurred in 5–10% of patients and lasted for an average of 1 day or less per cycle [17].
Approximately 3–5% of patients had amenorrhea each cycle [25]. Only 1.7% of women discontinued
Annovera due to unacceptable bleeding [26].
4.4. Vaginal Microbiome
Data from a microbiology substudy showed that the use of Annovera did not increase the rate of
vaginal infection and was not disruptive to the vaginal ecosystem [27]. Gynecological examinations
were conducted, and vaginal swabs were obtained for wet mount microscopy, Gram stain, and culture.
At the end of the 13-cycle study period, Annovera was removed from the vagina and cultured.
There were no significant changes in the detection rate of bacterial vaginosis (BV), vulvovaginal
candidiasis (VVC), or trichomoniasis throughout the study period [27]. Additionally, there was a
high level of agreement between the vaginal cultures and the cultures obtained from the surface
of Annovera [27]. The results suggest that the ring surface does not promote the proliferation of
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microorganisms, most notably, Staphlococcus aureus, which has been suggested as a causative factor of
toxic shock syndrome [27].
4.5. Adverse Reactions
The safety of Annovera was demonstrated in three 13-cycle, open-label clinical trials that enrolled
2308 healthy females aged 18–40 years across 20 United States sites and 7 international sites [26].
These women contributed 21,590 cycles of exposure for safety evaluation [26]. The most common
adverse reactions reported in ≥5% of clinical trial subjects are listed in Table 1 [26]. Most reactions
were considered mild, and most occurred within the first cycle, especially during the first few days
of initial insertion of the ring. Throughout the clinical trials, 12% of women discontinued Annovera
due to an adverse reaction (Table 2) [26]. Additionally, 25% of subjects reported at least 1 complete
expulsion during their use of Annovera; 1.4% of women discontinued Annovera due to expulsion of
the vaginal ring [26]. When using Annovera, women did not experience a clinically relevant increase
in weight [26]. In an acceptability substudy, women experiencing hormonal side effects reported
lower levels of satisfaction. It is, therefore, important to counsel patients appropriately about the
possibility of experiencing hormonal or other side effects, as well as give advice about managing these
experiences [23].
Table 1. List of most common adverse reactions reported in ≥5% of Annovera clinical trial subjects.
Adverse Reactions Reported by ≥5% of Subjects

%
(n = 2308)

Headache, including migraine
Nausea/vomiting
Vulvovaginal mycotic infection/vaginal candidiasis
Abdominal pain/lower/upper
Dysmenorrhea
Vaginal discharge
UTI/cystitis/pyelonephritis/genitourinary tract infection
Breast pain/tenderness/discomfort
Metrorrhagia/menstrual disorder
Diarrhea
Genital pruritus

38.6
25.0
14.5
13.3
12.5
11.8
10.0
9.5
7.5
7.2
5.5

Table 2. Adverse reactions leading to discontinuations in ≥1% of Annovera clinical trial subjects.
Adverse Reactions Leading to Discontinuation by ≥1% of Subjects

%
(n = 2308)

Metrorrhagia/menorrhagia
Headache, including migraine
Vaginal discharge/vulvovaginal mycotic infections
Nausea/vomiting

1.7
1.3
1.3
1.2

4.6. Venous Thromboembolism
Four nonfatal venous thromboembolisms (VTEs) occurred in the clinical trials and all 4 women
recovered. Three of the cases occurred in women with risk factors for VTE: one woman had Factor
V Leiden that was diagnosed after the event and two women were overweight. The fourth case
occurred in a woman who withdrew from the study before a clotting evaluation could be completed.
Post marketing studies are being conducted to further evaluate the risks of VTE [28]. Like other
combined hormonal contraceptives (CHCs), Annovera contains a boxed warning for women older than
35 years who smoke cigarettes since these women are at an increased risk of cardiovascular events [17].
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4.7. Use in Patients with BMI > 29 kg/m2
After approximately 50% enrollment, women with a BMI > 29 kg/m2 were excluded from
the clinical trials due to the occurrence of 2 VTEs in this population (see Section 4.4). Therefore,
out of 209 women with a BMI > 29 kg/m2 who enrolled in the study, only 36 completed the trial
thereby limiting the amount of clinical data that was collected in this population [26]. Accordingly,
while not contraindicated, the product labeling for Annovera has a limitation of use in women with a
BMI > 29 kg/m2 reflecting the limited population with a BMI > 29 kg/m2 that was evaluated in the
clinical trials [17]. Annovera’s Pearl Index does not change depending on a woman’s BMI [22].
4.8. Return to Fertility
After completion of the Annovera clinical trial, 290 women who were trying to become pregnant
or not continuing use of hormonal contraception were followed up for 6 months to assess the return to
fertility. One hundred percent of women in this follow-up study reported either the return of normal
menses or pregnancy. Of the women who desired pregnancy, 63% became pregnant within the first
6 months [22].
4.9. Concurrent Use of Vaginal Products
Annovera does not protect from sexually transmitted infections. Annovera is compatible with
male condoms made with natural rubber latex, polyisoprene, and polyurethane [17]. If there is a need
to treat a vaginal condition, water-based vaginal creams or oral therapies should be used rather than
oil-based vaginal suppositories [17]. Co-administration of oil-based miconazole vaginal suppositories
with Annovera was associated with increased systemic exposure of segesterone acetate and ethinyl
estradiol, whereas co-administration with a water-based cream miconazole formula was not [29].
Similarly, if women want to use a vaginal lubricant, only water-based lubricants should be used.
Silicone and oil-based lubricants, including coconut oil, will alter the Annovera vaginal system and
should be avoided.
5. Pharmacist Viewpoint
Annovera is a unique contraceptive, offering women an option for a self-administered method
of contraception that is long-lasting and easy to use. As a relatively new product, women may not
be familiar with the system. Pharmacists can play an important role in answering questions and
highlighting some of the important differences between Annovera and other hormonal contraceptives.
In states where pharmacists prescribe self-administered hormonal contraceptives, Annovera may be
an option to present to women interested in a long-lasting method that does not require daily pill
taking. It may be important to mention to potential users that the contraceptive ring systems are not
interchangeable, and instructions for use are specific to each product.
One of the key features of the Annovera system is its convenience. Upon initiation, the system
should be inserted vaginally for 21 days, removed for 7 days and then reinserted in this fashion for
13 cycles, providing a year of contraceptive protection. Because the same ring system is used for a year,
women do not have to return to the pharmacy or worry about having enough of their contraceptive
with them if they travel or are away at school. There is no need for a daily reminder to take a pill or
weekly reminder to change a patch and having a full year of contraception without having to worry
about obtaining supplies for a year is convenient. The system should be stored at room temperature;
no refrigeration is needed.
In providing patient consultation, pharmacists can inform users that Annovera is a well-tolerated
method of long-lasting, reversible contraception. Reported side effects are generally mild, self-limiting,
and are most often reported within the first cycle of use. Users can expect side effects similar to those
of other hormonal contraceptives such as headache, mild nausea, and some menstrual changes during
the initial use period. The system is flexible and can be inserted and removed using clean fingers.
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Once inserted, the system should remain in place and is not noticeable to most users. At the end of the
13 cycles, a new system can be prescribed for another year of contraception. A small compact case is
provided with the product for use during system removal days for discrete storage.
Women receiving Annovera may have questions about using the product. Frequently asked
questions/counseling points include:
5.1. Prior to Using Annovera
The ring system should be washed with mild soap and water then patted dry with a towel before
being inserted into the vagina. The system should be inserted as high into the vagina as is comfortable.
5.2. How to Start
Women who are initiating Annovera begin using the system as with other hormonal contraceptives.
Potential users should carefully read and understand the patient prescribing information [18].
For patients who have no hormonal contraceptive use in the preceding cycle or after Copper IUD
removal, the recommended regimen is for the patient to insert Annovera between ays 2 and 5 of her
regular menstrual period; no back-up contraception is needed. If menstrual cycles are irregular or if the
start is more than 5 days from the last menstrual bleeding, the woman should use an additional barrier
method during coitus, such as a male condom or spermicide, for the first 7 days of Annovera use.
Women already using a combination hormonal contraceptive method consistently and correctly and
who you are reasonably certain is not already pregnant may switch from her previous CHC to Annovera
on any day of the CHC cycle (day 1–28), without the need for back-up contraception, but no more
than 7 hormone-free days should occur before starting Annovera. No back-up is required for women
switching CHCs [17]. If a patient has no contraindications to the use of ethinyl estradiol (EE), she may
elect to switch from a progestin-only method to Annovera. If switching from progestin-only pills (POP),
she should begin Annovera at the time she would have taken her next POP pill. If switching from an
injection, she should begin Annovera at the time of her next scheduled injection. If switching from an
implant or intrauterine system (IUS), she should begin Annovera at the time of implant or IUS removal.
In all these cases, the woman should use a back-up method for the first 7 days of Annovera use [17]. If a
woman has no contraindications to the use of EE, Annovera may be initiated for contraception within
the first 5 days following a complete first trimester abortion or miscarriage without additional back-up
contraception. If more than 5 days have elapsed from the first trimester abortion or miscarriage,
then follow the instructions for patients who have not had hormonal contraceptive use in the preceding
cycle and a barrier method should be used from the time of the first trimester abortion or miscarriage
to the initiation of Annovera. Annovera should not be started earlier than 4 weeks after a second
trimester abortion or miscarriage due to the increased risk of thromboembolism [17]. Annovera should
not be started sooner than 4 weeks postpartum and only in females who choose not to breastfeed.
Prior to 4 weeks postpartum, there is an increased risk of thromboembolism. The initiation of Annovera
4 weeks or more postpartum should be accompanied by an additional back-up method for the first
7 days if the woman has not yet had a period. Consider the possibility of ovulation and contraception
occurring prior to initiating Annovera. Females who are breastfeeding should not use Annovera until
after weaning [17].
5.3. What Is the “Cycle” for Use
The ring system once inserted on day 1 should remain in place for 21 consecutive days. The ring
system can be removed for limited periods of time if desired but not exceeding 2 h over the course of
the 21 days [17]. Although the system can be removed for intercourse, it is not necessary. On day 21,
the ring system is removed and should be washed, dried, and stored in the compact case provided.
The ring system should be stored in the case when not in use.
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5.4. What If the System Comes Out
If the system comes out, it can be cleaned and reinserted. As long as the system has not been out
of the vagina for more than 2 h over the cycle, no backup method is needed [17]. If the ring has been
out of the vagina for more than 2 h during the cycle for any reason, a backup method of contraception
should be used for the next 7 days [17].
5.5. What to Do If the System Is Inserted Late or Early for Subsequent Cycles
If the system is reinserted after being out only 5–6 days, the system can remain in place until the
normal removal day [17]. If the system is inserted late, after being out more than 7 days, the system
should remain in place for the next 21 days and day 1 adjusted for future cycles [17]. A backup method
of protection should be used for the first 7 days. If the system is removed late, after more than 21 days,
the system should be removed as soon as remembered and reinserted 7 days later [17]. If the system is
removed 1–2 days early, the system should be reinserted 7 days later. The system can be left in place
during that next cycle until the usual removal date (22–23 days) or removed after 21 days to set a new
removal day [17].
5.6. How to Dispose of the System
The ring system should be disposed of using a pharmaceutical “take-back” bin or returned to
pharmacies with medication disposal services when possible. Users can also search the internet to
obtain an envelope for mailing the system to a pharmaceutical waste disposal company. If a take-back
option is unavailable, then discard in the waste receptacle out of reach of children and pets. The system
should not be flushed or cut-up and disposed of in the garbage [17].
6. Market Access and Coverage
As of June 2020, Annovera has 66% nationwide unrestricted access for patients with commercial
insurance. For Medicaid patients, Annovera has 46% unrestricted access in 38 states and Washington,
DC. States where Medicaid coverage exists are: AK, AL, AR, CO, CT, DC, FL, HI, ID, Il, IN, KS, KY, LA,
MA, MD, ME, MI, MO, MT, NC, ND, NE, NH, NJ, NM, NV, NY, OH, OR, RI, SC, SD, TN, TX, UT, VA,
WA, and WY. For more information, please reach out to TherapeuticsMD.
7. Conclusions
Annovera is a new, long-lasting, reversible contraceptive that is procedure-free and allows women
to be in control of their fertility for 1 year. Pharmacists nationwide may be dispensing this method
and counseling patients about its use. In states where pharmacists have contraception prescribing
authority, Annovera is the only long-lasting method that a pharmacist can prescribe and dispense on
site. The efficacy and safety profile of Annovera is similar to other CHCs, but it has the advantage
of supplying the patient with a 1 year supply of birth control after only one trip to the pharmacy.
Increased patient interest in long-acting methods, coupled with the unique attributes of Annovera,
makes this an important and relevant contraceptive option for patients, especially amidst the current
health crisis.
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